Table 2.

Observed and estimated SHBG changes during and between CIPII and SC insulin treatment.

	All patients (n=20)		Male (n=10)		Female (n=10)
	CIPII	SC insulin	CIPII	SC insulin	CIPII	SC insulin
0 months	58.0 [40.2, 75.6]	74.4 [40.4, 80.3]	57.1 [40.2, 70.4]	64.5 [39.9, 79.8]	62.1 [39.8, 98.5]	74.4 [40.7, 117.0]
3 months	43.1 [35.0, 76.1]	60.4 [42.0, 74.6]	38.7 [29.4, 62.3]	59.2 [42.7, 70.0]	66.9 [40.8, 100.7]	60.4 [40.1, 111.9]
6 months	47.7 [33.8, 73.3]	57.0 [40.4, 73.9]	38.3 [28.9, 64.5]	57.0 [40.4, 73.9]	64.4 [42.2, 87.6]	70.3 [38.0, 123.1]
Difference during treatment	−10.3 (−17.4, −3.2)*	−3.7 (−12.0, 4.6)	−15.8 (−24.2, −7.5)*	−3.1 (−12.2, 6.1)	−6.0 (−20.0, 8.0)	−4.3 (−22.4, 13.8)
Difference between treatment groups	−6.6 (95% CI: −17.5, 4.3)		−12.7 (−25.1, −0.4)*		−1.7 (−24.6, 21.1)

Data are shown as median [IQR] and estimated mean changes (95% CI) in nmol/L. Number of samples available for treatment mode: CIPII: 0 months (n=18), 3 months (n=19), 6 months (n=19). SC: 0 months (n=19), 3 months (n=19), 6 months (n=16).

*P < 0.05.